Pharmacological effects and tissue concentrations of amphetamine in rats pretreated with diethyldithiocarbamate (DDC), a dopamine-β-hydroxylase inhibitor

  • J. Jonsson
  • T. Lewander
Original Papers


Diethyldithiocarbamate (DDC), 400 mg kg−1,s. c., given 1 hour or 16 hours before administration of (+)-amphetamine sulphate, 4 mg kg−1, i. p., increased the tissue concentrations and reduced the rates of elimination of amphetamine in brain, plasma, lung, kidney and liver, and this was probably due to inhibition of amphetaminep-hydroxylation. Concomitantly, there was a prolongation of two pharmacological effects of the stimulanti. e. hyperthermia and motor hyperactivity, in similarly treated rats. However, a hypothermic effect of DDC itself initially counteracted the hyperthermic response to amphetamine, indicating a dual interaction between the two drugs. The multiple biochemical actions of DDC and similar chemical agents seriously confound the interpretation of the results when using these dopamine (β-hydroxylase inhibitors,e. g. as pharmacological tools in elucidating the mechanism of action of other drugs.


Diethyldithiocarbamate amphetamine metabolism drug interactions body temperature motor activity rat 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. (1).
    Lewander, T. and Jonsson, J. (1973), Drugs and certain conditions interfering with the metabolism and excretion of amphetamine in the rat.In: Psychopharmacology, sexual disorders and drug abuse. Eds: Ban, T. A., Boissier, J. R., Gessa, G. al., North-Holland Publishing Company, Amsterdam-London and Avicenum, Czechoslovak Medical Press, Prague, p. 625–635.Google Scholar
  2. (2).
    Lewander, T. (1969), Influence of various psychoactive drugs on thein vivo metabolism ofd-amphetamine in the rat. Europ. J. Pharmacol.,6, 38–44.CrossRefGoogle Scholar
  3. (3).
    Jonsson, J. and Gunne, L.-M. (1972), Interaction of fenfluramine withd-amphetamine-induced excitatory behaviour and hyperthermia. Europ. J. Pharmacol.,19, 52–55.CrossRefGoogle Scholar
  4. (4).
    Randrup, A. and Munkvad, I. (1970), Biochemical, anatomical and physiological investigations of stereotyped behaviour induced by amphetamines.In: International Symposium on Amphetamines and Related Compounds. Eds: Costa, E. and Garattini, S. Raven Press, New York, p. 695–713.Google Scholar
  5. (5).
    Randrup, A. and Scheel-Krüger, J. (1966), Diethyldithiocarbamate and amphetamine stereotype behaviour. J. Pharm. Pharmacol.,18, 752.PubMedGoogle Scholar
  6. (6).
    D’Encarnacao, P. S., D’Encarnacao, P. and Tapp, J. T. (1969), Potentiation of amphetamine induced psychomotor activity by diethyldithiocarbamate. Arch. int. Pharmacodyn.,182, 186–189.PubMedGoogle Scholar
  7. (7).
    Mayer, O. and Eybl, V. (1971), The effect of diethyldithiocarbamate on amphetamine-induced behaviour in rats. J. Pharm. Pharmacol.,23, 894–896.PubMedGoogle Scholar
  8. (8).
    Corrodi, H., Fuxe, K., Ljundgahl, A. and Ögren, S.-O. (1970), Studies on the action of some psychoactive drugs on central noradrenaline neurones after inhibition of dopamine-β-hydroxylase. Brain Res.,24, 451–470.CrossRefPubMedGoogle Scholar
  9. (9).
    Jonsson, J. and Lewander, T. (1973), Effects of diethyldithiocarbamate and ethanol on thein vivo metabolism and pharmacokinetics of amphetamine in the rat. J. Pharm. Pharmacol.,25, 589–591.PubMedGoogle Scholar
  10. (10).
    Jonsson, J. and Lewander, T. (1974), Effects of the dopamine-β-hydroxylase inhibitor FLA 63 on the kinetics of elimination of amphetamine in the rat. J. Pharm. Pharmacol.,26, 907–909.PubMedGoogle Scholar
  11. (11).
    Lai, S., Sourkes, P. L. and Missala, K. (1974), The effect of certain tranquilizers, chlorpromazine metabolites and diethyldithiocarbamate on tissue amphetamine levels in the rat. Arch. int. Pharmacodyn.,207, 122–130.Google Scholar
  12. (12).
    Maickel, R. P., Cox, R. H. Jr., Miller, F. P., Segal, D. S. and Russel, R. W. (1969), Correlation of brain levels of drugs with behavioural effects. J. Pharmacol, exp. Ther.,165, 216–224.Google Scholar
  13. (13).
    Lewander, T. (1971), On the presence ofp-hydroxyno-rephedrine in the rat brain and heart in relation to changes in catecholamine levels after administration of amphetamine. Acta Pharmacol, toxicol. (Kbh.),29, 33–48.Google Scholar
  14. (14).
    Jonsson, J. (1976), Influence of various drugs on the metabolism of amphetamine in rat liver microsomes and perfused liver preparations. Submitted for publication.Google Scholar
  15. (15).
    Pfeifer, A. K., Galambos, E. and Gyorgy, L. (1966), Some central nervous properties of diethyldithiocarbamate. J. Pharm. Pharmacol.,18, 254.PubMedGoogle Scholar
  16. (16).
    Strömme, J. H. (1965), Metabolism of disulfiram and diethyldithiocarbamate in rats with demonstration of anin vivo ethanol induced inhibition of the glucuronic acid conjugation of the thiol. Biochem. Pharmacol.,14, 391–408.Google Scholar
  17. (17).
    Thorne, G. D. and Ludwig, R. A. (1962), The dithiocarbamates and related compounds, Elsevier, Amsterdam-New York.Google Scholar
  18. (18).
    Olesen, O. V. (1966), Disulfiram (AntabuseR) as inhibitor of phenytoin metabolism. Acta Pharmacol, toxicol. (Kbh.),24, 1075–1080.Google Scholar
  19. (19).
    Stripp, B., Greene, F. E. and Gillette, J. R. (1969), Disulfiram impairment of drug metabolism by rat liver microsomes. J. Pharmacol, exp. Ther.,170, 347–354.Google Scholar
  20. (20).
    Deitrich, R. A. and Erwin, V. G. (1971), Mechanism of the inhibition of aldehyde dehydrogenasein vivo by disulfiram and diethyldithiocarbamate. Molec. Pharmacol.,7, 301–307.Google Scholar
  21. (21).
    Vesell, E. S., Passanonti, G. T. and Lee, C. H. (1971), Impairment of drug metabolism by disulfiram in man. Clin. Pharmacol, and Ther.,12, 758–792.Google Scholar
  22. (22).
    Notten, W. R. F. and Hendersson, T. Th. (1973), Effect of disulfiram on the urinaryd-glucaric acid excretion and activity of some enzymes involved in drug metabolism in guinea pig. Arch. int. Pharmacodyn.,205, 199–208.PubMedGoogle Scholar
  23. (23).
    Goldstein, N., Anagnoste, B., Lauber, E. and McKereglan, M. R. (1964), Inhibition of dopamine-β-hydroxylase by disulfiram. Life sci.,3, 163–167.CrossRefGoogle Scholar
  24. (24).
    Musacchio, J. M., Kopin, I. J. and Snyder, H. S. (1964), Effects of disulfiram on tissue norepinephrine content and subcellular distribution of dopamine, tyramine and their β-hydroxylated metabolites. Life Sci.,3, 769–775.CrossRefPubMedGoogle Scholar
  25. (25).
    Collins, G. G. S. (1965), Inhibition of dopamines-β-oxydase by diehtyldithiocarbamate. J. Pharm. Pharmacol.,17, 526–527.PubMedGoogle Scholar
  26. (26).
    Hashimoto, Y., Ohi, Y. and Imaizumi, R. (1965), Inhibition of brain dopamine-β-oxidasein vivo by disulfiram. Jap. J. Pharmacol.,15, 123–124.Google Scholar
  27. (27).
    Thoenen, H., Haefely, W., Gey, K. F. and Hürlimann, A. (1965), Diminished effects of symphatetic nerve stimulation in cats pretreated with disulfiram: Liberation of dopamine as sympathetic transmitter. Life Sci.,4, 2033–2038.CrossRefPubMedGoogle Scholar
  28. (28).
    Carlsson, A., Lindkvist, M., Fuxe, K. and Hökfelt, T. (1966), Histochemical and biochemical effects of diethyldithiocarbamate on tissue catecholamines. J. Pharm. Pharmacol.,18, 60–62.PubMedGoogle Scholar
  29. (29).
    Musacchio, J. M., Goldstein, M., Anagnoste, B., Poch, G. and Kopin, I. J. (1966), Inhibition of dopamines-β-hydroxylase by disulfiramin vivo. J. Pharmacol, exp. Ther.,152, 56–61.Google Scholar
  30. (30).
    Carlsson, A., Fuxe, K., Hökfelt, T. (1967), Failure of dopamine to accumulate in central noradrenaline neurons after depletion with diethyldithiocarbamate. J. Pharm. Pharmacol.,19, 481–483.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1976

Authors and Affiliations

  • J. Jonsson
    • 1
  • T. Lewander
    • 1
  1. 1.Psychiatric Research CenterUniversity of Uppsala, Ulleräker HospitalUpssalaSweden

Personalised recommendations